{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 114,
        "end": 120
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 159,
        "end": 168
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 142,
        "end": 147
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 177,
        "end": 182
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 193,
        "end": 202
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 142,
        "end": 158
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 177,
        "end": 190
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "19655247_7",
  "text": "Pharmacogenetics studies illustrate the potential of genetics to impact on response to therapy , as observed with SLC6A4 and responses to the 5-HT3 antagonist alosetron and the 5-HT4 agonist , tegaserod ."
}
